Pediatric trials are quietly underway to support prescribing GLP-1 medications for obesity in children younger than 12, despite concerns about their long-term effects on developing bodies
The SELECT trial is a major breakthrough, says Yale Medicine cardiologist Harlan Krumholz, MD, SM, explaining that while semaglutide [given as Ozempic] was already known to lower the risk of heart disease in people with diabetes, the SELECT trial was the first to show that Wegovy, which contains a higher dose of semaglutide, also lowers that risk even in people who dont have diabetes
Semaglutide converts white adipose tissues into brown adipose tissues, a phenomenon called adipose tissue browning, and reduces dysfunctional adiposity in obesity
LingvayIHansenTMacuraSMarreMNauckMAde la RosaRet al
Mean increases in resting heart rate have been observed in randomized clinical trials of semaglutide and are documented in FDA prescribing information